For US Healthcare Professionals

Updated Guidance: VYJUVEK is now approved for use from birth, can be applied by a caregiver or patient at-home, has an increased weekly volume, & has the flexibility of being removed at your next dressing change.

Connect With Us
Updated Guidance
VYJUVEK is now approved for use from birth, can be applied by a caregiver or patient at-home, has an increased weekly volume, & has the flexibility of being removed at your next dressing change.

About VYJUVEK

For the treatment of dystrophic epidermolysis bullosa (DEB)

Proven durable wound closure for DEB patients with VYJUVEK1,2

With demonstrated long-term efficacy and safety, VYJUVEK is the FIRST and ONLY topical therapy that delivers new COL7A1 genes for healing with anchoring fibrils resulting in complete and durable wound closure.2
Now with more convenient application options to fit your patient’s routine
Now with more convenient application options to fit your patient’s routine

Mechanism of Action

1

Topical COL7A1 gene delivery

  • In DEB, the mutated COL7A1 gene leads to reduced or absent collagen VII, causing insufficient formation of anchoring fibrils and resulting in fragile skin1

  • VYJUVEK delivers 2 functional copies of the COL7A1 gene directly into keratinocyte and fibroblast cells of open wounds3

VYJUVEK™ MOA - Topical COL7A1 Gene delivery Downward arrow indicating flow direction
2

Anchoring fibril production

  • The functional genes allow the body to produce type VII collagen protein, which is used to create and assemble anchoring fibrils1

VYJUVEK™ MOA - Anchoring fibril Production Downward arrow indicating flow direction
3

Promotion of wound healing

  • Anchoring fibrils help bind the epidermis and dermis together to promote wound closure1

VYJUVEK™ MOA - Wound closure

See how VYJUVEK works

See how VYJUVEK was studied

Study Design
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in adult and pediatric patients (from birth) with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds until the next dressing change following treatment. Wear protective gloves when assisting patients with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.


  • Please see Important Safety Information above and click here for full Prescribing Information.
REFERENCES:

1. VYJUVEK [prescribing information]. Krystal Biotech, Inc.; 2023.

2. Paller AS, Guide SV, Deigo A, et al. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa. J Dermatolog Treat. 2024;35(1):2350232. doi:10.1080/09546634.2024.2350232

3. Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022. doi:10.1038/s41591-022-01737-y

IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE

VYJUVEK is a topical gel indicated for the treatment of wounds in adult and pediatric patients (from birth) with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Accidental Exposure to VYJUVEK gel: VYJUVEK will not replicate in the subject’s cells and does not integrate into the subject cells’ native genetic material. For precautions, avoid direct contact with treated wounds (e.g., touching or scratching) and dressings of treated wounds until the next dressing change following treatment. Wear protective gloves when assisting patients with changing wound dressings and handling the disposal. In the event of accidental exposure (e.g., through a splash to the eyes or mucous membranes), flush with clean water for at least 15 minutes.

Clean all surfaces that may have come in contact with VYJUVEK biological suspension or gel and treat all spills with a virucidal agent.

Dispose all materials (e.g., vial, syringe, cleaning materials) that may have come in contact with VYJUVEK biological suspension or gel into a biohazard container.

ADVERSE REACTIONS

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose.


  • Please see Important Safety Information above and click here for full Prescribing Information.
REFERENCES:

1. VYJUVEK [prescribing information]. Krystal Biotech, Inc.; 2023.

2. Paller AS, Guide SV, Deigo A, et al. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa. J Dermatolog Treat. 2024;35(1):2350232. doi:10.1080/09546634.2024.2350232

3. Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022. doi:10.1038/s41591-022-01737-y